Karim Karer, M.D., PhD, and other colleagues from Wake Forest University School of Medicine in Salem, NC, analyzed data from 1,654 men who were a part of a prostate cancer clinical trial. The men in the study all had multiple negative biopsies, PSA screenings and received a genetic score based on testing of a panel of 33 single nucleotide polymorphisms that had been previously associated with prostate cancer.
The researchers found that, after adjusting the clinical factors and family history, the genetic score was a significant factor of a subsequent positive biopsy.
“Adding genetic markers to clinical parameters may improve cancer risk prediction. The improvement is modest but maybe helpful for better determining the need for repeat prostate biopsy,” Kadar and colleagues conclude. “The clinical impact of these results requires further study.”
Most of these diagnoses are made with a standard transrectal biopsy administered in the office by urologists. However, often times a patient will have a continued rising PSA, despite having had a negative office biopsy. This causes anxiety for patients and physicians. Fortunately ChicagoProstateCenter has developed Stereotactic Transperineal Prostate Biopsy, or STPB. This is the most comprehensive, sophisticated prostate biopsy technique available, diagnosing 40% more cancer than the standard transrectal office procedure —- cancer that would have otherwise gone undetected. The STPB procedure:
- Diagnosing 40% more cancer
- One-time, out-patient procedure (no hospital stay needed)
- Minimally invasive (no incisions or stitches)
- Performed under general anesthesia with no discomfort
- Infection rate negligible
- Confidence in exact location of cancer
- Minimal, if any, post-operative pain
- Return to normal activity within a day